A Phase 1 study of ARVN001 for the treatment of diabetic macular edema (DME)
Latest Information Update: 17 Mar 2022
At a glance
- Drugs Triamcinolone (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- 10 Mar 2022 Status changed from planning to recruiting according to Clearside Biomedical media release,
- 10 Mar 2022 According to Clearside Biomedical media release, Arctic Vision announced that they have started dosing patients in this trial.
- 06 Dec 2021 New trial record